News
This twice-a-year shot to prevent HIV could stop transmission — if people can get it
The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the U.S. and abroad will get access to the powerful new option.
Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...
Stocktwits on MSN17h
Gilead Earns Analyst Praise As FDA Clears Yeztugo For Biannual HIV PreventionGilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...
The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.
Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.
The United States Food and Drug Administration (FDA) has approved long-acting injectable lenacapavir for HIV prevention. The ...
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...
A United Nations agency has urged the pharmaceutical company Gilead Sciences to lower the price of the long acting antiviral treatment lenacapavir following the US Food and Drug Administration (FDA)’s ...
Zacks Investment Research on MSN1d
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-TermIt doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback